Physician profile
James E Warrington
NPI 1912919234
$914.51
in general payments reported to CMS, 2019-2025
13 companies · $78.86 in 2025
The $78.86 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $426 · 2020: $124 · 2021: $52.69 · 2022: $79.46 · 2023: $71.01 · 2024: $82.06 · 2025: $78.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $231.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $349.97 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $137.12 | 2019-2021 | |
| Abbvie INC. | $95.03 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $73.28 | 2019 | |
| Novartis Pharmaceuticals Corporation | $66.37 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $37.58 | 2023 | Rexulti |
| Smith+Nephew, INC. | $33.61 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $33.43 | 2023 | Austedo Xr |
| Glaxosmithkline, LLC. | $23.22 | 2019 | |
| Lilly USA, LLC | $22.90 | 2025 | Mounjaro, Zepbound |
| Kowa Pharmaceuticals America, INC. | $15.64 | 2022 | |
| Paratek Pharmaceuticals, INC. | $13.60 | 2024 | Nuzyra |
| Astellas Pharma US INC | $12.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Warrington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.